AIRLINK 176.82 Decreased By ▼ -0.07 (-0.04%)
BOP 11.09 Decreased By ▼ -0.26 (-2.29%)
CNERGY 7.94 No Change ▼ 0.00 (0%)
FCCL 44.94 Decreased By ▼ -0.47 (-1.04%)
FFL 16.11 Decreased By ▼ -0.21 (-1.29%)
FLYNG 28.28 Increased By ▲ 0.43 (1.54%)
HUBC 141.78 Increased By ▲ 2.80 (2.01%)
HUMNL 13.25 Increased By ▲ 0.05 (0.38%)
KEL 4.43 Increased By ▲ 0.02 (0.45%)
KOSM 6.03 Decreased By ▼ -0.11 (-1.79%)
MLCF 58.45 Decreased By ▼ -0.41 (-0.7%)
OGDC 224.19 Increased By ▲ 6.02 (2.76%)
PACE 5.93 Decreased By ▼ -0.04 (-0.67%)
PAEL 45.90 Increased By ▲ 0.03 (0.07%)
PIAHCLA 18.16 Decreased By ▼ -0.07 (-0.38%)
PIBTL 10.60 Increased By ▲ 0.05 (0.47%)
POWER 11.30 Decreased By ▼ -0.21 (-1.82%)
PPL 185.48 Increased By ▲ 0.98 (0.53%)
PRL 36.91 Decreased By ▼ -0.13 (-0.35%)
PTC 23.69 Decreased By ▼ -0.39 (-1.62%)
SEARL 98.40 Increased By ▲ 0.74 (0.76%)
SILK 1.15 No Change ▼ 0.00 (0%)
SSGC 37.38 Increased By ▲ 0.06 (0.16%)
SYM 15.01 Decreased By ▼ -0.33 (-2.15%)
TELE 7.82 Decreased By ▼ -0.05 (-0.64%)
TPLP 10.96 Decreased By ▼ -0.15 (-1.35%)
TRG 66.14 Decreased By ▼ -4.06 (-5.78%)
WAVESAPP 10.88 Decreased By ▼ -0.22 (-1.98%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
YOUW 3.81 Decreased By ▼ -0.01 (-0.26%)
AIRLINK 176.82 Decreased By ▼ -0.07 (-0.04%)
BOP 11.09 Decreased By ▼ -0.26 (-2.29%)
CNERGY 7.94 No Change ▼ 0.00 (0%)
FCCL 44.94 Decreased By ▼ -0.47 (-1.04%)
FFL 16.11 Decreased By ▼ -0.21 (-1.29%)
FLYNG 28.28 Increased By ▲ 0.43 (1.54%)
HUBC 141.78 Increased By ▲ 2.80 (2.01%)
HUMNL 13.25 Increased By ▲ 0.05 (0.38%)
KEL 4.43 Increased By ▲ 0.02 (0.45%)
KOSM 6.03 Decreased By ▼ -0.11 (-1.79%)
MLCF 58.45 Decreased By ▼ -0.41 (-0.7%)
OGDC 224.19 Increased By ▲ 6.02 (2.76%)
PACE 5.93 Decreased By ▼ -0.04 (-0.67%)
PAEL 45.90 Increased By ▲ 0.03 (0.07%)
PIAHCLA 18.16 Decreased By ▼ -0.07 (-0.38%)
PIBTL 10.60 Increased By ▲ 0.05 (0.47%)
POWER 11.30 Decreased By ▼ -0.21 (-1.82%)
PPL 185.48 Increased By ▲ 0.98 (0.53%)
PRL 36.91 Decreased By ▼ -0.13 (-0.35%)
PTC 23.69 Decreased By ▼ -0.39 (-1.62%)
SEARL 98.40 Increased By ▲ 0.74 (0.76%)
SILK 1.15 No Change ▼ 0.00 (0%)
SSGC 37.38 Increased By ▲ 0.06 (0.16%)
SYM 15.01 Decreased By ▼ -0.33 (-2.15%)
TELE 7.82 Decreased By ▼ -0.05 (-0.64%)
TPLP 10.96 Decreased By ▼ -0.15 (-1.35%)
TRG 66.14 Decreased By ▼ -4.06 (-5.78%)
WAVESAPP 10.88 Decreased By ▼ -0.22 (-1.98%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
YOUW 3.81 Decreased By ▼ -0.01 (-0.26%)
BR100 12,435 Increased By 81.3 (0.66%)
BR30 38,584 Increased By 460.3 (1.21%)
KSE100 116,633 Increased By 193.6 (0.17%)
KSE30 35,822 Increased By 118.6 (0.33%)

KARACHI: Committed to giving back to society, Biologica in partnership with JS Group and Medipak organised a ceremony to mark the handing over of 35,000+ Covid-19 rapid antigen test kits to Interactive Research and Development (IRD), funded by the Bill and Melinda Gates Foundation.

The ceremony was attended by Faisal Ismail, CEO-Biologica, Naveed Khalid Chowdhry, CEO-Medipak, Aneeta Pasha, Country Director-IRD Pakistan along with other senior officials.

IRD is a research and health delivery organization that creates novel health infrastructures, by leveraging technology and developing capacity with community stakeholders in areas of infectious and non-communicable diseases and maternal and child healthcare, across the globe.

Speaking at the occasion, Faisal Ismail stated, “We are honoured to be associated with IRD in an effort to reduce the transmission of COVID-19. We are also excited to announce that the local production of COVID-19 Rapid Antigen Test Kits will be commencing soon in collaboration with Medipak and Mologic/ Global Access Diagnostic UK, a leading innovator in rapid diagnostic technology.”

Sharing his thoughts, Naveed Khalid Chowdhry mentioned, “Keeping with Medipak’s philosophy, ‘we give the best to life’, we are honoured to have facilitated this initial supply of imported COVID-19 Rapid Antigen Tests to IRD. With our 40 years of manufacturing expertise in pharmaceuticals and medical devices, we proudly look forward to the imminent launch of local COVID-19 rapid antigen tests from our latest facility for IVDs”.

Aneeta Pasha, said, “Building upon key learnings from our integrated COVID community response model to the outbreak in 2020, IRD’s WellCheck program aims to increase access to essential health services and prevent the transmission of COVID through fast and efficient screening and rapid testing. Using a holistic services approach, IRD works to address both physical and mental health and foster resilience and safety in schools as we continue to battle against COVID-19.”

IRD’s wellness program WellCheck provides holistic health support to organizations and through the WellCheck School Program, will be working to strengthen health responses at schools for students in grades 7 – 12.

Biologica and Medipak have partnered to establish a modern facility in Lahore to locally produce Rapid Antigen Kits and other In Vitro Diagnostics (IVDs) in technical collaboration with Mologic/ Global Access Diagnostics UK so that people in Pakistan can have access to medical devices at affordable prices. This initiative will contribute towards healthcare, provide employment opportunities, and have great export potential in line with the vision of the Government of Pakistan.

Copyright Business Recorder, 2022

Comments

Comments are closed.